PYC pyc therapeutics limited

0.40%

$1.27

First time I heard of David Lane was this time last year...

First 2 Last

Share
Profile

Follow
ds

7,131 Posts.

12/04/17

15:53

Post #: 24034269
Share

Originally posted by waynesworld ↑

Professor Sir David Lane is now listed as one of Phylogica's ongoing academic research partners. What brings the discoverer of P53 and one of the world's most eminent cancer scientists into our orbit?

P53, the Guardian of the Genome is faulty or inactivated in the majority of cancers. Is it possible that targeting mutated P53 and Myc is a potential and powerful therapeutic opportunity?

There is research paper on the Dual targeting of P53 and c-Myc in leukaemic stem cells published in the June 2016 edition of Nature. Could leukaemia be a target or possibly is the target more likely to be triple negative breast cancer? Treatments for TNBC is one of the most urgent needs in breast cancer therapeutics. It is also listed as a potential targeted indication under the Myc program on Phylogica's website.

Expand

First time I heard of David Lane was this time last year regarding the CRUK grants selection panel.

http://www.cancerresearchuk.org/fun...rand-challenge-award/panels#members_gallery_6

Good to see there is a formal link now - no idea if we have ended up going for a grant this year but my understanding was that there were people who wanted to partner with us for a grant this year and they were of the calibre of Gerard Evan and Laura Soucek. Maybe this has all fallen flat but David has been aware of PYC for at least a year.

PYC Price at posting: 3.6¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

First 2 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.27		Change 0.005(0.40%)		Mkt cap ! $740.7M

Open	High	Low	Value	Volume
$1.27	$1.29	$1.27	$406.0K	319.3K

Buyers (Bids)

No.	Vol.	Price($)
1	13987	$1.27

Sellers (Offers)

Price($)	Vol.	No.
$1.29	1380	1

View Market Depth

No.	Vol.	Price($)
1	13987	1.265
2	16380	1.260
3	14380	1.255
3	103380	1.250
1	4000	1.225

Price($)	Vol.	No.
1.285	1380	1
1.290	27010	3
1.295	25880	2
1.300	59168	4
1.325	9001	1

Last trade - 16.10pm 27/06/2025 (20 minute delay)

PYC (ASX) Chart

First time I heard of David Lane was this time last year...

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Australia’s gas crisis is here – and dying coal plants aren’t helping

Monash IVF shares cater 25% – Disaster or deep-value play?

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

First time I heard of David Lane was this time last year...

Top Stories

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Australia’s gas crisis is here – and dying coal plants aren’t helping

Monash IVF shares cater 25% – Disaster or deep-value play?

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News